Attovia Therapeutics: president and CEO Fu Tao received 538,300 shares

What happened

• Fu Tao, president and CEO and director, received a derivative award of 538,300 shares on Aug 4, 2026. The reported price is $0.00 and the total reported value is $0. This Form 4 is an amendment to the Form 4 filed Aug 6, 2026.

Key details

• Transaction date and code: Aug 4, 2026; code A (award/grant).
• Price: $0.00 per share; total reported value $0.
• Vesting: 25% of the options vest on Aug 4, 2027; the remaining options vest in equal monthly installments over the following 36 months, subject to continued service (footnote F1).
• Shares owned after the transaction: the filing states no changes are being reported with respect to the reporting person's beneficial ownership.
• Amendment: this Form 4 amendment was filed Oct 8, 2026 and replaces the original Form 4 (filed Aug 6, 2026) to report the filing under the reporting person's CIK.

Why it may matter

• The filing reports an award of derivative securities (options) that vest over time; it is not a market sale or purchase.
• A filing does not show why the insider traded or why the company acted.